Evidence from post-mortem human brains, animal studies and cell culture models has implicated neuroinflammation in the aetiology of chronic neuropathologies including Alzheimer's and Parkinson's diseases. Although the neuroinflammatory response is considered detrimental in contributing to these pathologies, the underlying mechanisms are still not well understood. The type-I interferons (IFNs) have been well characterised in the periphery and are known to initiate/ modulate the immune response. Recently, they have been implicated in ageing and we have also demonstrated increased type-I IFN expression in post-mortem human Alzheimer's and Parkinson's disease brains. We hypothesise that the type-I IFNs are key drivers of the damaging, selfperpetuating pro-inflammatory response that contributes to these chronic neuropathologies. In support of this, we have recently confirmed in models of Alzheimer's and Parkinson's disease that mice lacking the type-I IFN receptor (IFNAR1), display an attenuated neuroinflammatory response with subsequent neuroprotection. To further investigate type-I IFNmediated neuroinflammation and the specific CNS cell types involved, this study treated primary cultured wild-type and IFNAR1 À/À neurons or mixed glia with the mitochondrial complex I inhibitor, rotenone. Wild-type neurons and glia treated with 3 nM and 25 nM rotenone, respectively, exhibited a pro-inflammatory response, including increased type-I IFN expression that was attenuated in cells lacking IFNAR1.
Interferons (IFNs) are pleiotropic cytokines with a known role in the host immune response to infections and pathogens (de Weerd et al. 2012) . Type-I IFNs (IFN-a and IFN-b) exert their effects through the classical Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling pathway, leading to the secretion of classical pro-inflammatory cytokines [including tumour necrosis factor-a (TNF-a), Interleukin-6 (IL-6) and interleukin1-b (IL1-b)] and induction of apoptosis. Indeed, without the presence of type-I IFNs an innate inflammatory response is unable to be generated (de Weerd et al. 2012) . In the CNS, both neurons and glial cells are known to produce and respond to type-I IFNs (Owens et al. 2014) and increased type-I IFN expression has been linked to CNS disorders including systemic lupus erythematosus (Meyer 2009 ), HIV-encephalopathy (Rho et al. 1995) and Aicardi-Goutieres syndrome (Crow et al. 2006) . More recently, the type-I IFNs have been linked to the elevated neuroinflammatory response in the lysosomal storage disease, Gaucher disease (Vitner et al. 2016) .
Recently, a role for the type-I IFNs in ageing has also been proposed. Specifically, a type-I IFN-dependent gene expression profile was reported in the choroid plexus of aged mice and humans (Baruch et al. 2014) . Blocking of type-I IFN signalling restored cognitive function and hippocampal neurogenesis in aged mice. We have recently confirmed increased type-I IFN levels in post-mortem human Alzheimer's disease (AD) brains and in the APP/PS1 mouse (Taylor et al. 2014) . Furthermore, mice with attenuated type-I IFN signalling (APP/PS1 mice crossed with IFNAR1 À/À mice) display an altered neuroinflammatory phenotype with reduced microglial activation and some cognitive improvement at 9 months of age (Minter et al. 2016a) . Recently, a number of animal models have also supported a detrimental role for type-I IFN signalling in Parkinson's disease (PD). Qin et al. (2016) demonstrated a type-I IFN signature in an a-synuclein rat model, with attenuation of the downstream JAK-STAT signalling protecting against dopaminergic (DA) neurodegeneration (Qin et al. 2016) . We have confirmed that genetically or pharmacologically blocking the IFN receptor, IFNAR1, to diminish type-I IFN signalling attenuates the early neuroinflammatory response in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD (Main et al. 2016) . These mice displayed reduced levels of pro-inflammatory cytokines and microglial activation, which correlated with decreased MPTP-induced nigral degeneration and improvements in striatal dopamine levels and behavioural outcomes. These studies suggest that type-I IFNs have deleterious effects in age-related neurodegenerative disorders.
In this study, we used an in vitro rotenone model to further characterise the cellular source and contribution of the type-I IFNs to the neuroinflammatory response that contributes to neuronal cell death. Rotenone is a mitochondrial complex I inhibitor known to be neurotoxic to both dopaminergic (Choi et al. 2015) and non-dopaminergic neurons (Chen et al. 2006) , with this attributed in part to its effects on mitochondrial respiration and elevated oxidative stress. Significantly, in studies with primary cultured glia/microglia, it has also been shown to induce oxidative stress and a neuroinflammatory response, including increased pro-inflammatory cytokine secretion (Ye et al. 2016) . We hypothesise that the type-I IFNs are critical mediators of rotenone-induced neuroinflammation and neuronal cell death. Here, we present evidence for a critical role of the type-I IFNs in mediating the neuroinflammatory response induced by rotenone in vitro in both primary cultured neurons and glia. Importantly, we demonstrate that the attenuation of type-I IFN signalling is neuroprotective in this model confirming the crucial role these cytokines play in mediating the neuroinflammatory response that contributes to neuronal cell death in chronic neuropathologies.
Methods

Mice
IFNAR1
À/À mice were initially generated by (Hwang et al. 1995) with wild-type C57Bl/6 time-mated female mice sourced from Australian Resources Centre (ARC, Western Australia). All pregnant female mice were housed under specific pathogen-free conditions in a 20-24°C room with a 12 h light/dark cycle and with food and water ad libitum according to standard animal care conditions at the Biomedical Research Facility, University of Melbourne. All animal studies complied with and were approved by the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences Animal Ethics Committee (Ethics No. 1212477).
Isolation of mixed cortical and hippocampal neurons
Mixed cortical and hippocampal neurons were isolated from day 14-16 embryos as previously described (Taylor et al. 2005; Crack et al. 2006) . The purity of cultures was determined to be > 95% neurons as indicated by Fox-3/NeuN and glial fibrillary acidic protein staining to identify neurons and glia respectively. Neuronal cultures were utilised for treatment at 9 days in vitro.
Primary mixed cortical and hippocampal glial cultures
Mixed primary glial cells were isolated from post-natal P0-P1 C57BL/6 wild-type and IFNAR1 À/À genotypes as previously described (Minter et al. 2016a) . Cells were cultured in T75 cm 2 flasks in Dulbecco's modified Eagle's medium (containing 20% FBS (Fetal Bovine Serum), 0.5% penicillin-streptomycin). Dulbecco's modified Eagle's medium culture medium was changed every 3-4 days and cells cultured until reaching approximately 90-95% confluency. Cells were used at passage 2-3 and were plated into 10-cm dishes for experimental use.
Cell treatments
Rotenone (Sigma-Aldrich, Castle Hill, NSW, Australia) was prepared fresh for each experiment, to a 12.7 lM stock solution in dimethylsulfoxide (DMSO), which was diluted further to desired final concentrations in treatment medium before use (final concentration of DMSO < 0.001% v/v). For 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and caspase-3 assays, cells were treated with vehicle or rotenone for 24 h or 8, 24 and 48 h, respectively. For mRNA analysis, neurons and glial cells were treated over a time course with either 3 or 25 nM rotenone, respectively. MAR1-5A3 (monoclonal antibody specifically targeted to block IFNAR1; Leinco Technologies, St. Louis, MO, USA) was diluted in sterile H 2 O to a stock concentration of 2.3 mg/mL and stored in aliquots at À80°C. Cells were pre-treated with 2.5 mg/mL MAR-1 or IgG isotype control in appropriate culture media for 30 min prior to rotenone treatment. Cell viability of neurons was then determined by a MTT assay after 24 h or the media from glia removed after 24, 48 or 72 h to measure type-I IFN levels by reporter assay. MTT cell viability assay Cell viability was measured by the ability of cells to metabolise MTT reagent (2 mg/mL; Sigma, Castle Hill, NSW, Australia) to a formazan product. Following rotenone treatment, MTT was added to culture and incubated for 2 h at 37°C/5% CO 2 . Culture medium was then removed and 200 lL DMSO was added to each well to solubilise the formazan product, followed by transferral to a 96-well plate and absorbance was determined at 595 nm. All experiments were performed in triplicate and viability was expressed as a percentage of Abs 595 nm of the vehicle control.
RNA extraction and cDNA synthesis Cells were lysed and homogenised in 1 mL of Trizol â reagent (Invitrogen, Life Technologies, Scoresby, Vic., Australia). RNA was isolated as per manufacturers guidelines, with concentration and purity of the RNA assessed using the NanoDrop 1000 Spectrophotometer (Thermo Scientific, Scoresby, Vic., Australia). RNA was reverse transcribed into cDNA using a high-capacity RNA-to-cDNA reverse transcription kit (Applied Biosystems, Life Technologies, Scoresby, Vic., Australia) in accordance with manufactures guidelines. Briefly, reverse transcription of 1 lg RNA to cDNA was performed using a thermocycler (Eppendorf, North Ryde, NSW, Australia) under the following conditions: 25°C/10 min, 37°C/ 120 min, 95°C/5 min, 10 min/4°C. The resulting cDNA was diluted 1 : 3 with DEPC-H 2 O and stored at À80°C for QPCR analysis.
Quantitative real-time polymerase chain reaction (QPCR) All QPCR was performed in standard 384-well plates (4309849; Applied Biosystems) using the 7900ht fast real-time PCR system (Applied Biosystems) and reactions for a given sample were performed in triplicate. All Taqman gene expression assays were purchased commercially (431182; Applied Biosystems) and reactions were performed under the following conditions with the listed primers:
Step no. For SYBR â green-based detection, gene-specific primers were synthesised commercially (Geneworks, Thebarton, SA, Australia) and reactions were performed under the following thermal conditions:
Step no. The software SDS 2.4 (Applied Biosciences) was used to generate threshold cycle (Ct) values. Ct values were collected and relative gene transcript levels were calculated using the ddCT method as described in (Winer et al. 1999 ).
Caspase-3 activity assay Caspase-3 activity was measured by quantitating the ability of cells to cleave Ac-DEVD-pNa into free colorimetric pNA using the colorimetric CaspACE TM assay system (G7220; Promega, Alexandria, NSW, Australia) as per manufacturer's guidelines. Briefly, 50 lg/well of protein extract [as determined by Bradford assay (Bio-Rad Laboratories, Gladesville, NSW, Australia)] was loaded in triplicate in a 96-well plate, and incubated at 37°C for 4 h. Absorbance was read at 405 nM and levels of cleaved pNa released for each sample was calculated relative to a standard pNa substrate curve.
B16-Blue
TM type-I IFN reporter assay B16-Blue TM IFNa/b reporter cells (bb-ifnt1; Gibco/Invitrogen, Scoresby, Vic., Australia) were used to measure type-I IFNs produced by primary cultured glial cell lines. B16-Blue TM murine type-I IFN reporter cells were derived from a murine B16 melanoma cell line of C57BL/6 origin. These cells have been stably transfected with a secreted embryonic alkaline phosphatase (SEAP) reporter gene under the control of the IFNa/b-inducible ISG54 promoter enhanced by a multimeric interferon stimulated response elements. Stimulation of these cells with murine IFNa/b triggers the production of SEAP by the activation of the Interferon-regulatory factor (IRF)-inducible promoter. Levels of SEAP in the supernatant are then determined with QUANTI-Blue TM (rep-qb1; Gibco/Invitrogen), a colorimetric enzyme assay developed to determine any alkaline phosphatase (AP) activity in a biological sample. The colour of QUANTI-Blue TM changes from pink to purple/blue and absorbance determined at 630 nm using a Multiskan Ascent plate reader (Thermo Scientific).
Following treatments, conditioned media was collected and added to the B16-Blue TM reporter cells (bb-ifnt1; Invivogen, San Diego, CA, USA) for 20-24 h. To validate reporter activity, B16-Blue TM reporter cells were concurrently treated with IFN-b (0-1000 IU/mL; PBL Assay Science, Piscataway, NJ, USA) to generate a standard curve for normalisation of results. QUANTI-Blue TM was added in a 1 : 1 v/v ratio to detect SEAP activity and incubated for 24 h at 37°C/5% CO 2 . Following SEAP detection, 200 lL was transferred into a 96-well plate and absorbance determined at 630 nm using a Multiskan Ascent plate reader.
ELISA Murine IL-6, IL-1b and IL-10 (BD Biosciences, North Ryde, NSW, Australia) ELISAs were performed according to manufacturer's instructions. A quantity of 100 lg of protein was loaded per well in duplicate. Protein concentrations of individual samples were determined using a linear curve of mouse IL-6, IL-1b or IL-10 standards (4-250 pg/mL).
Statistical analysis
All data are expressed as mean AE SEM, n = number of experimental replicates. QPCR, ELISA and MTT assay data were analysed using a two-way ANOVA, with subsequent Bonferroni post-hoc tests. Power values for each test were calculated post-hoc using G*Power (version 3.1, http://gpower.hhu.de/), based upon the effect size, group number and sample size. For all statistical tests p < 0.05 was accepted as being statistically significant.
Results
IFNAR1
À/À primary cultured neurons are less sensitive to rotenone-induced toxicity We have previously confirmed that IFNAR1 À/À mice are less susceptible to MPTP-induced DA cell death in vivo (Main et al. 2016) . To confirm that reduced type-I IFN signalling was neuroprotective in vitro, wild-type and IFNAR1
À/À neurons were treated with rotenone (1-5 nM) for 24 h and cell viability was assessed by a MTT assay. IFNAR1
À/À neurons were less susceptible to cell death induced by 1 nM (WT: 74.7 AE 6.2% vs. IFNAR1
: 94.9 AE 3.5% compared to vehicle, n = 5, ***p < 0.001, t = 4.176, DF = 3) and 3 nM (WT: 75.1 AE 2.8% vs. IFNAR1 À/À : 93.3 AE 2.8% n = 4, **p < 0.01, t = 3.588, DF = 3) rotenone compared to wild-type cultures (Fig. 1a) . It is well established that rotenone can induce neuronal death via caspase-3-mediated apoptosis (Ahmadi et al. 2003; Pei et al. 2003 : 83.0 AE 6.4 pmol/50 lg, n = 6, *p < 0.05, t = 2.847, DF = 3) compared to wild-type neurons (Fig. 1b) .
To correlate our in vitro viability studies with a reduced pro-inflammatory response (including the type-I IFNs) in the IFNAR1 À/À neurons, cells were treated with rotenone over a 2-48 h time-course. QPCR analysis was performed to determine expression of both the type-I IFNs and the classical pro-inflammatory cytokines, IL-1b and TNF-a. Rotenone induced a significant increase in IFN-a expression in wild-type neurons at 2 h (WT: 8.5 AE 1.1-fold vs. IFNAR1 À/À : 1.4 AE 0.4-fold compared to vehicle, n = 5, t = 4.053, ***p < 0.001, DF = 5) and 4 h (WT: 6.5 AE 1.8-fold vs. IFNAR1 À/À : 0.8 AE 0.2-fold compared to vehicle, n = 6, **p < 0.01, t = 3.653, DF = 5) that was absent in the WT and IFNAR1 À/À neurons (n = 6) were treated with 3 nM rotenone for 8, 24 or 48 h. Cells were harvested and caspase-3 levels assessed by measuring pNA levels as determined by referencing to a known pNA standard curve. Data were expressed as the mean AE SEM. Statistical analysis was done by a two-way ANOVA with Bonferroni's multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001).
À/À neurons (Fig. 2a) . Similarly, there was a significant difference in the levels of IFN-b between wildtype and IFNAR1 À/À neurons at 4 h (WT: 4.4 AE 1.0-fold vs.
À/À : 1.2 AE 0.2-fold compared to vehicle, n = 6, **p < 0.01, t = 3.272, DF = 5) (Fig. 2b) . At 48 h, there was a second wave of increased IFN-a (WT: 8.0 AE 1.6-fold vs. IFNAR1 À/À : 3.0 AE 1.0-fold compared to vehicle, **p < 0.01, n = 8, t = 3.588, DF = 5) and IFN-b (WT: 5.3 AE 0.9-fold vs. IFNAR1 À/À : 2.3 AE 0.9-fold compared to vehicle, n = 7, **p < 0.01, t = 3.408, DF = 5) expression in the rotenone-treated wild-type neurons that was attenuated in the IFNAR1 À/À cells. Over the entire rotenone time-course, the knockout neurons also displayed reduced expression of IL1-b and TNF-a, with significant differences at 24 h (WT: 2.3 AE 0.4-fold vs. IFNAR1 À/À : 0.6 AE 0.1-fold compared to vehicle, n = 6 *p < 0.05, t = 2.957, DF = 4) and 48 h (WT: 2.7 AE 1.2-fold vs. IFNAR1 À/À : 0.7 AE 0.1-fold compared to vehicle, n = 7 **p < 0.01, t = 3.529, DF = 4) and 4 h (WT: 4.1 AE 1.2-fold vs. IFNAR1 À/À : 1.4 AE 0.4-fold compared to vehicle, n = 6, *p < 0.05, t = 3.126, DF = 4), respectively ( Fig. 2c and d) .
À/À glia display an attenuated pro-inflammatory response induced by rotenone Glial cells (microglia and astrocytes) are considered the predominant cell type involved in the neuroinflammatory response in both acute and chronic brain neuropathologies. We were interested in identifying whether type-I IFN signalling was also critical in mediating the glial response to rotenone. Once it was confirmed rotenone was not toxic to the primary mixed glial cultures at the doses of 1-100 nM (data not shown), a time course of 24-72 h with 25 nM rotenone was performed. Expression of IFN-a and IFN-b was determined by QPCR analysis with a type-I IFN reporter cell line used to measure type-I IFN levels released into the glial media. At 24 h, rotenone induced an increase in type-I IFN expression in wild-type glia with mRNA levels of IFN-a significantly elevated compared to IFNAR1 À/À cells (WT:
5.3 AE 1.5-fold vs. IFNAR1 À/À : 1.5 AE 0.4-fold compared to vehicle, n = 6, *p < 0.05, t = 2.652, DF = 3) (Fig. 3a) . Similarly, at 72 h, there was an attenuated response in the knockout cells with reduced expression of both IFN-a (WT: 7.3 AE 1.3-fold vs. IFNAR1 À/À : 0.5 AE 0.1-fold compared to vehicle, n = 6, **p < 0.01, t = 3.670, DF = 3) and IFN-b (WT: 7.3 AE 2.0-fold vs. IFNAR1 À/À : 1.2 AE 0.5-fold compared to vehicle, n = 6, *p < 0.05, t = 2.821, DF = 3) ( Fig. 3a and b) . In support of the reduced mRNA expression, IFNAR1 À/À glia demonstrated significantly reduced type-I IFN protein levels at both 24 h (WT: 37.9 AE 6.9 IU/mL vs. IFNAR1
À/À : 6.2 AE 2.5 IU/mL, n = 4, ***p < 0.01, t = 3.988, DF = 3) and 72 h (WT: 79.8 AE 8.2 IU/mL vs. IFNAR1 À/À : 40.7 AE 13.9 IU/mL, n = 4, ***p < 0.001, t = 4.157, DF = 3) (Fig. 3c) . Analysis of pro-inflammatory cytokine expression by ELISA confirmed a significant increase in IL-6 levels at 24 h (WT: 200.7 AE 186.7 pg/ 200 lL vs. IFNAR1 À/À : 34.3 AE 9.0 pg/200 lL, n = 6, **p < 0.01, t = 3.245, DF = 3) (Fig. 3d) 58.6 AE 9.9 pg/200 lL, n = 6, **p < 0.05, t = 3.245, DF = 3) (Fig. 3e) (Fig. 3f ). This suggests that type-I IFN signalling is a critical mediator of the pro-inflammatory response induced by rotenone in primary glia.
Wild-type, but not IFNAR1 À/À glia, display increased expression of M1-like markers in response to rotenone Studies of the innate immune response have highlighted its complexity with a myriad of factors, their receptors and subsequent signalling pathways involved. Akin to their peripheral counterparts, in an attempt to simplify the response, the terms 'M1' and 'M2' have been widely used to designate pro-and anti-inflammatory microglia (and to a lesser extent astrocytes), respectively (reviewed in Cherry et al. 2014) . However, the use of this 'M1' of 'M2' nomenclature is now considered an oversimplification, with evidence demonstrating that microglia exist as a continuum of the two or as a mixed phenotype in response to specific stimuli (reviewed in Moehle and West 2015) . The increased pro-inflammatory cytokine expression induced by rotenone in wild-type mixed glia ( Fig. 3d and e) did suggest a propensity of the cultures to adopt a more 'M1-like' phenotype overall. However to confirm this, mRNA expression of M1 (CD11b, CD16, CD86 and iNOS) and M2 (ARG1 and YM1) markers was analysed by QPCR. Expression of CD11b (WT: 2.9 AE 0.7-fold vs. IFNAR1 À/ À : 0.7 AE 0.1-fold compared to vehicle, n = 6, ***p < 0.001, t = 5.260, DF = 3), CD16 (WT: 2.3 AE 0.4-fold vs. IFNAR1 À/À : 0.9 AE 0.1-fold compared to vehicle, n = 6, ***p < 0.001, t = 4.380, DF = 3) and CD86 (WT: 2.8 AE 1.2-fold vs. IFNAR1 À/À : 1.0 AE 0.1-fold compared to vehicle, n = 6, *p < 0.05, t = 2.922, DF = 3) were all significantly up-regulated in wild-type but not IFNAR1
cultures following 72 h rotenone treatment (Fig. 4a-c) .
Rotenone also induced an early increase in iNOS expression at 24 h in wild-type glia, a response that was attenuated in the knockout cultures (WT: 2.1 AE 0.5-fold vs. IFNAR1 À/À :
1.0 AE 0.1-fold compared to vehicle, n = 3, *p < 0.05, t = 2.862, DF = 3) (Fig. 4d) . In contrast, there was no significant difference in ARG1 and YM1 expression between the wild-type and IFNAR1 À/À cells with an up-regulation in both genotypes. (Fig. 4e and f) . This data suggests although wild-type glial cells do adopt a mixed phenotype exhibiting Tumour necrosis factor-a (e) and the antiinflammatory IL-10 (f) were assessed by ELISA. All data were expressed relative to the vehicle control as the mean AE SEM, n = 6. Statistical analysis was done by a two-way ANOVA with Bonferroni's multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001).
both pro-and anti-inflammatory responses; these cultures are over-represented by the former. The IFNAR1 À/À cells in contrast, with little evidence of increased M1 marker expression by rotenone, display a more anti-inflammatory phenotype as a whole. The elevated levels of IL-10 accompanied by minimal increases in IL-6 or IL-1b in these cultures supports this (Fig. 3d-f ).
Conditioned media from rotenone-treated IFNAR1 À/À glia is less cytotoxic to primary cultured neurons Wild-type or IFNAR1 À/À primary glia were treated with 25 nM rotenone for 24, 48 or 72 h before the media was removed and placed onto primary cultured wild-type neurons for 24 h and cell viability determined by a MTT assay. Increased cell death was seen in wild-type neurons that were exposed to media from rotenone-treated (24 h) wild-type glia compared to IFNAR1
À/À glia (78.4 AE 2.4% vs. 92.2 AE 2.2% compared to vehicle, n = 7, *p < 0.05, t = 3.148, DF = 3, two-way ANOVA) (Fig. 5) . A significant difference in viability was also seen with media from glia treated with 25 nM rotenone for 48 h (WT: 73.41 AE 3.9% vs. IFNAR1 À/À : 84.7 AE 3.8% compared to vehicle, n = 7, *p < 0.05, t = 2.640, DF = 3, two-way ANOVA, Bonferroni's post hoc test). The reduced cytotoxicity of media from IFNAR1 À/À glia supports the previous data identifying reduced pro-inflammatory cytokine expression as a result of attenuated type-I IFN signalling.
MAR-1, an IFNAR1 blocking monoclonal antibody, is neuroprotective against rotenone-induced cell death
To further characterise the neuroprotective effects of blocking type-I IFN signalling, wild-type primary neurons were glia is less neurotoxic than wild-type glia to wild-type neurons. Primary cultured wild-type (WT) and IFNAR1 À/À mixed glia were treated with 25 nM rotenone or vehicle for 24-72 h before the media was removed an applied to primary wild-type neurons for an additional 24 h. Cell viability was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay with data expressed relative to the vehicle control as the mean AE SEM, n = 7. Statistical analysis was done by a two-way ANOVA with Bonferroni's multiple comparison test (*p < 0.05).
incubated with a blocking monoclonal IFNAR1 antibody, MAR-1 (2.5 mg/mL) or IgG isotype control for 30 min before being treated with 3 nM rotenone for 24 h and cell viability assessed by a MTT assay. In the presence of the IgG control antibody, rotenone-treated neurons demonstrated 75.6 AE 2.9% viability (compared to IgG/vehicle control) (Fig. 6a) . In contrast, there was a significant attenuation of rotenone-induced cell death in the MAR-1 treated cells (90.4 AE 5.2% compared to MAR-1/vehicle control) (n = 3, *p < 0.05, t = 3.495, DF = 3, one-way ANOVA, Bonferroni's post hoc test). MAR-1 was able to effectively block the rotenone-induced type-I IFN production in primary cultured glia (Fig. 6b) as measured by a reporter assay with a significant reduction at 72 h (IgG/rotenone: 38.9 AE 8.9 IU/ mL compared to IgG/vehicle vs. to MAR-1/rotenone 13.2 AE 1.9 IU/mL, n = 3, **p < 0.01, t = 4.495, DF = 3, two-way ANOVA, Bonferroni's post hoc test). In addition, media from glia treated with rotenone in the presence of MAR-1 was significantly less cytotoxic to wild-type neurons compared to media from IgG/rotenone-treated glia (IgG/ rotenone: 70.2 AE 6.3% cell viability compared to MAR-1/ rotenone: 87.9 AE 4.3% cell viability (relative to vehicle controls) (n = 3, *p < 0.05, t = 3.277, DF = 3, two-way ANOVA, Bonferroni's post hoc test). This data supports the neuroprotective effects seen with MAR-1 in vivo and suggests that this is in part because of its ability to attenuate the glial type-I IFN production to these toxins.
Discussion
Evidence suggests that neuroinflammation is a fundamental process that although beneficial following acute neural injury, contributes to the neurodegeneration in chronic neuropathologies. However, the key mediator of this inflammatory response and the mechanism of action that can lead to cell death remain undefined. Type-I IFNs possess pleiotropic biological functions including antiviral and antiproliferative capacities and are considered to be the key initiator of the inflammatory response. Type-I IFN-IFNAR signalling and subsequent activation through the classical JAK/STAT cascade leads to an up-regulation in pro-inflammatory gene transcription including the type-I IFNs themselves (de Weerd et al. 2012) . This signalling cascade has been well characterised in the periphery, however, its contribution to the neuroinflammatory response in chronic CNS disorders, such as AD and PD, is still not known. Our previous data implicated the type-I IFNs in the MPTP model of PD (Main et al. 2016) and in the APP/PS1 mouse model of AD (Minter et al. 2016a) with an attenuated neuroinflammatory response in mice lacking IFNAR1. We hypothesised that glial cells are the major drivers of this damaging response; however, as both neurons and glia are known to produce and respond to the type-I IFNs, this study further characterised type-I IFN signalling in specific CNS cell types following exposure to the neurotoxin rotenone. Rotenone is a complex I inhibitor known to induce oxidative stress and neuronal cell death but recently it has also been reported to activate microglia with subsequent pro-inflammatory cytokine secretion (Ye et al. 2016) . We confirmed that rotenone induces a pro-inflammatory response that includes increased type-I IFN expression, Neuronal cell death induced by conditioned media from rotenonetreated primary glia was reduced in the presence of MAR-1 (2.5 lg) compared to IgG-treated cells. All data were expressed relative to the vehicle control and as the mean AE SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
in both primary cultured neurons and glia. Removal of the type-I IFN receptor, IFNAR1, in these cells attenuated this pro-inflammatory response with subsequent neuroprotection against rotenone-induced neuronal cell death. Significantly, by therapeutically targeting IFNAR1 through the monoclonal antibody, MAR-1, we were also able to provide some protection against cell death induced by rotenone. The resident microglia are considered the primary immune cell in the CNS and therefore have been implicated as the major driver of neuroinflammation in both AD and PD (reviewed in Taylor et al. 2013; Minter et al. 2016b) . However, neurons and astrocytes are also involved in this response and it is known that neurons also express and respond to type-I IFNs through toll-like receptor stimulation (Carpentier et al. 2005; Costello and Lynch 2013) . In this study, we demonstrate that rotenone treatment stimulates an early up-regulation (within 2 h) in type-I IFN expression in wild-type primary neuronal cultures. Furthermore, this type-I IFN production occurs before the up-regulation of proinflammatory cytokines (IL1-b and TNF-a) supporting a role for the type-I IFNs as mediators or regulators of the neuroinflammatory environment induced by rotenone. Similarly, we have previously reported that the Ab1-42-induced IFN response in primary neurons occurs prior to the induction of other pro-inflammatory cytokines (Taylor et al. 2014) . This has implications for the human conditions where hallmark features of neuroinflammation including the expression of IL-1b and TNF-a have been detected in both the CSF from AD and PD patients and in post-mortem brains. Additionally, studies have demonstrated that neurons are sensitive to IL-1b and TNF-a cytotoxicity (Kaur et al. 2014 ). Attenuation of this pro-inflammatory response through TNFa À/À mice (Ferger et al. 2004) , soluble TNF-a inhibitors (McCoy et al. 2006 ) and anti-IL-1b neutralising antibodies (Arai et al. 2006) are neuroprotective, further demonstrating the role of the inflammatory response in disease progression. Similarly, our data reveals that primary cultured neurons from IFNAR1 À/À mice not only have attenuated type-I IFN expression, but also reduced rotenone-induced pro-inflammatory cytokine production of TNF-a and IL-1b, compared to wild-type controls. This reduced response in the IFNAR1 À/À neurons correlated with decreased rotenoneinduced cell death compared to wild-type cultures that was associated with reduced caspase-3 activity. In support of this, BE(2) M17 neuroblastoma cells stably over-expressing a shRNA IFNAR1 knockdown construct also displayed reduced rotenone-induced neuroinflammation and cell death (data not shown), while we have previously confirmed an attenuated neuroinflammatory response in IFNAR1 À/À neurons with subsequent protection against Ab1-42-induced cell death (Taylor et al. 2014) . Indeed, IFN-b has been shown to have deleterious effects on neuronal survival, by regulating signalling molecules that promote intrinsic apoptosis (Dedoni et al. 2010) . These results suggest a key modulatory role for type-I IFNs in not only the pro-inflammatory response but also in the downstream pro-apoptotic signalling mechanisms induced by rotenone and other cellular insults. In addition, it supports our previous findings in the MPTP mouse model of PD that identified increased DA neuronal cell survival in the absence of IFNAR1 (Main et al. 2016) . Rotenone was also shown to be a potent stimulator of the type-I IFNs in primary glial cells. Previous studies have confirmed a pro-inflammatory response in rotenone-treated mixed primary cultured glia or BV2 microglia cells with increased expression of IL1-b and TNF-a reported (Chang et al. 2013; Liang et al. 2015) . Type-I IFN levels were upregulated within 24 h and in contrast to the IL-6 and IL-1b levels which returned to near control levels at 72 h, there was a second 'wave' of IFN production at the latter time-point. This could be attributed to secondary signalling pathways involving damage-associated molecular patterns leading to elevated type-I IFNs (Gao et al. 2011 ) and mimics what we also saw in glial cells in response to Ab1-42 (Minter et al. 2016a) . Again, highlighting the modulatory role of the IFN-IFNAR1 signalling cascade, this pro-inflammatory cytokine expression was diminished in the IFNAR1 À/À glia. In contrast, expression of the anti-inflammatory-IL-10 was only up-regulated in the IFNAR1 À/À glia. This imbalance in the WT glia only (and not in the IFNAR1 À/À cells) was further corroborated by the mRNA expression of M1-microglial markers. While 'M2' markers were unchanged in either rotenone-treated WT or IFNAR1 À/À mixed glia cultures, the expression of 'M1' markers, CD11b, CD16, CD86 and iNOS were all elevated in the WT (but not IFNAR1 À/À ) cultures. We therefore concluded similar to our in vivo MPTP study, rotenone induces a more M1-like phenotype in glia that is associated with the classical pro-inflammatory response as previously reported (Du et al. 2014) . Interestingly, this contrasted to the up-regulation in 'M2' marker expression that we previously saw in Ab1-42-treated IFNAR1 À/À glia (and in APP/PS1/IFNAR1 À/À mice), suggesting in the absence of type-I IFN signalling, these cells were adopting an anti-inflammatory phenotype (Minter et al. 2016a ). However, taken together these studies do suggest that the type-I IFNs drive or influence glia to adopt a proinflammatory phenotype. Indeed, the detrimental effects of this increased pro-inflammatory cytokine secretion was confirmed when the media from the rotenone-treated wildtype glia was placed onto primary cultured neurons. The reduced neurotoxicity in the absence of a glial mediated IFN response is similar to that reported with the type-2 IFN, IFNc (Mount et al. 2007 ) and indeed with our own studies with Ab-treated neurons/glia (Minter et al. 2016a) .
We have previously confirmed that blocking the type-I IFN receptor through the use of a monoclonal antibody, is effective in reducing type-I IFN expression in the brain, proinflammatory cytokine expression and ultimately nigral degeneration induced by MPTP (Main et al. 2016) . This study has confirmed that rotenone induces type-I IFNs in both neurons and glia and critically, abrogation of this response through MAR-1 treatment, afforded some protection against subsequent neuronal cell death. Identifying the cellular source of the type-I IFNs and confirming the implications of targeting this response were critical to confirm this pathway as a true therapeutic target for future drug design. We do not propose that type-I IFN signalling causes AD or PD, however, we hypothesise that the type-I IFNs are critical mediators of the neuroinflammatory response that contributes to the neuronal degeneration in these diseases. Our studies support the notion that therapeutically targeting this response, particularly that occurring in the glial cells of the CNS, may provide an alternative strategy to reduce neurodegeneration and slow the progression of these debilitating diseases.
